The North West Fund for Biomedical and SPARK Impact
The £25m North West Fund for Biomedical, which is managed by SPARK Impact, is part of the £185m evergreen fund provided by the European Investment Bank (EIB) and European Regional Development Fund (ERDF), to supply debt and equity funding to small and medium sized enterprises in the North West of England. The North West Fund for Biomedical is accessible to a broad range of companies including those developing pharmaceuticals, new diagnostics and medical devices, and those working in the fields of clinical research, contract manufacturing and analytical services.
EV is one of the leading providers of venture and growth capital high growth unquoted companies located throughout the UK. It manages a range of funds and is able to provide up to £2 million to new or existing companies and invests at all stages of investment; particularly MBOs, development capital and high growth early stage technology opportunities. It is regulated by the Financial Services Authority (FSA) and is a full member of the British Venture Capital Association (BVCA).
Sarum Capital LLP
Sarum Capital LLP is an appointed representative of Sturgeon Ventures LLP, which is authorised and regulated by the Financial Services Authority (FSA). Sarum Partners, that manage the fund, is a team of strategic management consultants to the oncology sector. The Partners bring together 4 distinct skill sets; oncology entrepreneurs who have successfully built and sold over 12 oncology companies between them, commercial scientists who have discovered and invented technologies in the cancer arena, practising clinical oncologists who are on the 'coal face', and financial expertise in biotechnology and valuation techniques.
Imprimatur is an operational investment business focused on the commercialisation of high-growth IP backed opportunities from Universities, research institutes and other sources. Operating on an international basis, the company is represented by an experienced team with a track record of creating shareholder value and with an in-depth understanding of all aspects of what is required to successfully commercialise early stage technology opportunities.